

Table 14-1.02
Summary of End of Study Data

	Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)	Total (N=254)	p-value[1]
Completion Status:					
Completed Week 24	60 (70%)	28 (33%)	30 (36%)	118 (46%)	<.0001
Early Termination (prior to Week 24)	26 (30%)	56 (67%)	54 (64%)	136 (54%)	
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
Reason for Early Termination (prior to Week 24):					
Adverse Event	8 (9%)	44 (52%)	39 (46%)	91 (36%)	<.0001
Death	1 (1%)	1 (1%)	0 (0%)	2 (1%)	
Lack of Efficacy[2]	3 (3%)	0 (0%)	1 (1%)	4 (2%)	0.3281
Lost to Follow-up	1 (1%)	0 (0%)	0 (0%)	1 (0%)	
Subject decided to withdraw	9 (10%)	8 (10%)	8 (10%)	25 (10%)	
Physician decided to withdraw subject	1 (1%)	0 (0%)	2 (2%)	3 (1%)	
Protocol criteria not met	1 (1%)	0 (0%)	2 (2%)	3 (1%)	
Protocol violation	1 (1%)	1 (1%)	1 (1%)	3 (1%)	
Sponsor decision	1 (1%)	2 (2%)	1 (1%)	4 (2%)	
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	

[1] Fisher's exact test.

[2] Based on either patient/caregiver perception or physician perception.